Two anti-PD-1 agents, nivolumab and pembrolizumab, and one anti-PD-L1 agent, atezolizumab, have been approved over the last three years for the treatment of metastatic NSCLC and other agents are under investigation. The gene discussed is CD274; the disease is non-small cell lung carcinoma.